Study identifier:1033GR/0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomised in practice evaluation of the influence of patient's understanding of her disease and therapy on persistence and compliance to adjuvant therapy for post-menopausal hormone sensitive early breast cancer
Breast Cancer
-
No
Anastrozole
Female
4923
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
1 Standard routine care for breast cancer | Drug: Anastrozole oral Other Name: Arimidex Other Name: ZD1033 |
2 Standard + Intervention arm: standard routine care for breast cancer and additional information material via post | Drug: Anastrozole oral Other Name: Arimidex Other Name: ZD1033 |